DHJJ Financial Advisors’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$581K Sell
4,522
-10
-0.2% -$1.17K 0.17% 102
2026
Q1
$545K Hold
4,532
0.18% 93
2025
Q4
$477K Hold
4,532
0.16% 107
2025
Q3
$380K Hold
4,532
0.13% 123
2025
Q2
$359K Sell
4,532
-132
-3% -$10.5K 0.13% 121
2025
Q1
$419K Hold
4,664
0.17% 103
2024
Q4
$464K Hold
4,664
0.18% 93
2024
Q3
$530K Hold
4,664
0.21% 86
2024
Q2
$577K Hold
4,664
0.24% 79
2024
Q1
$615K Hold
4,664
0.27% 70
2023
Q4
$508K Hold
4,664
0.24% 73
2023
Q3
$480K Sell
4,664
-1,350
-22% -$146K 0.24% 75
2023
Q2
$694K Hold
6,014
0.36% 58
2023
Q1
$640K Hold
6,014
0.35% 64
2022
Q4
$667K Buy
6,014
+232
+4% +$23.7K 0.38% 58
2022
Q3
$498K Hold
5,782
0.29% 72
2022
Q2
$527K Hold
5,782
0.29% 71
2022
Q1
$483K Hold
5,782
0.23% 83
2021
Q4
$443K Hold
5,782
0.21% 87
2021
Q3
$434K Hold
5,782
0.22% 83
2021
Q2
$450K Sell
5,782
-278
-5% -$20.7K 0.24% 78
2021
Q1
$446K Hold
6,060
0.26% 70
2020
Q4
$473K Buy
+6,060
New +$463K 0.3% 62

Other funds holding MRK

DHJJ Financial Advisors's MRK Position: Q2 2026 in Review

DHJJ Financial Advisors reduced its Merck (MRK) stake by 0.22% in Q2 2026, selling an estimated $1.17K and leaving 4,522 shares worth $581K. The position accounts for 0.17% of the portfolio, ranked #102.

DHJJ Financial Advisors first reported a position in MRK in Q4 2020 and has held it in 23 quarters since. The position peaked at $694K in Q2 2023. 1,867 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • DHJJ Financial Advisors held 4,522 shares of Merck worth $581K as of Q2 2026.
  • DHJJ Financial Advisors sold 10 Merck shares in Q2 2026, an estimated $1.17K.
  • Merck made up 0.17% of DHJJ Financial Advisors's portfolio in Q2 2026, its #102 holding.
  • DHJJ Financial Advisors first reported a position in Merck in Q4 2020 and has held it in 23 quarters since.
  • DHJJ Financial Advisors's Merck position peaked at $694K in Q2 2023.
  • 1,867 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on DHJJ Financial Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.